Abbvie raises sales outlook of two new drugs to more than $17.5 billion in 2025
The company's previous sales outlook for Skyrizi and Rinvoq in 2025 was more than $15 billion
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Humira
Pfizer and BioNTech’s COVID-19 vaccine Comirnaty tops the list of best-selling drugs
Ends the nine-year reign of AbbVie’s Humira as the world’s best-selling pharma product
Anti-TNF therapies could treat patients with COVID-19-related ARDS
This would reduce COVID-19 mortality, as about 17 of COVID-19 patients develop ARDS, states GlobalData
Higher dose of Gilead-Galapagos drug meets ulcerative colitis study goals
Filgotinib is also in advanced stages of testing against multiple types of inflammatory conditions including rheumatoid arthritis,…
AbbVie completes acquisition of Allergan
The transaction significantly expands and diversifies AbbVie’s revenue base and complements existing leadership positions in…
Novartis arthritis drug fails to prove it is significantly better than rival
Novartis said Cosentyx, when used to treat active psoriatic arthritis, "narrowly missed statistical significance for superiority"…
AbbVie looks beyond Humira with $63 billion deal for Botox-maker Allergan
AbbVie has long been under pressure to diversify its portfolio and its shares have lost more than a third of their value since…